The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall survival from the third prespecified interim analysis of the trial would also favor pembrolizumab was uncertain. METHODS: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 1:1 ratio) participants with clear-cell renal-cell carcinoma who had an increased risk of recurrence after surgery to receive pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks for up to 17 cycles (approximately 1 year) or until recurrence, the occurrence of unacceptable toxic effects, or withdrawal of consent. A significant improvement in disease-free survival according to investigator assessment (the primary end point) was shown previously. Overall survival was the key secondary end point. Safety was a secondary end point. RESULTS: A total of 496 participants were assigned to receive pembrolizumab and 498 to receive placebo. As of September 15, 2023, the median follow-up was 57.2 months. The disease-free survival benefit was consistent with that in previous analyses (hazard ratio for recurrence or death, 0.72; 95% confidence interval [CI], 0.59 to 0.87). A significant improvement in overall survival was observed with pembrolizumab as compared with placebo (hazard ratio for death, 0.62; 95% CI, 0.44 to 0.87; P = 0.005). The estimated overall survival at 48 months was 91.2% in the pembrolizumab group, as compared with 86.0% in the placebo group; the benefit was consistent across key subgroups. Pembrolizumab was associated with a higher incidence of serious adverse events of any cause (20.7%, vs. 11.5% with placebo) and of grade 3 or 4 adverse events related to pembrolizumab or placebo (18.6% vs. 1.2%). No deaths were attributed to pembrolizumab therapy. CONCLUSIONS: Adjuvant pembrolizumab was associated with a significant and clinically meaningful improvement in overall survival, as compared with placebo, among participants with clear-cell renal-cell carcinoma at increased risk for recurrence after surgery. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564 ClinicalTrials.gov number, NCT03142334.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791
Self-citationLenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035716 · Cited by 1,766
Self-citationRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz056 · Cited by 1,151
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Chang, Y.-H., Hajek, J., Symeonides, S. N., Lee, J. L., Sarwar, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106391 · Cited by 785
Self-citationAdjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Ravaud, A., Motzer, R. J., Pandha, H. S., George, D. J., Pantuck, A. J., Patel, A., Chang, Y.-H., Escudier, B., Donskov, F., Magheli, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611406 · Cited by 782
Self-citationChoueiri, T. K., Halabi, S., Sanford, B. L., Hahn, O., Michaelson, M. D., Walsh, M. K., Feldman, D. R., Olencki, T., Picus, J., Small, E. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7398 · Cited by 720
Self-citationHaas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00559-6 · Cited by 630
Self-citationMotzer, R. J., Haas, N. B., Donskov, F., Gross-Goupil, M., Varlamov, S., Kopyltsov, E., Lee, J. L., Melichar, B., Rini, B. I., Choueiri, T. K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.5324 · Cited by 382
Self-citationDuan, J., Cui, L., Zhao, X., Bai, H., Cai, S., Wang, G., Zhao, Z., Zhao, J., Chen, S., Song, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5367 · Cited by 349
Self-citationPowles, T., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Gurney, H., Chang, Y.-H., Lee, J. L., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00487-9 · Cited by 294
Self-citationGross-Goupil, M., Kwon, T. G., Eto, M., Ye, D., Miyake, H., Seo, S. I., Byun, S.-S., Lee, J. L., Master, V., Jin, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy454 · Cited by 259
Self-citationPal, S. K., Uzzo, R., Karam, J. A., Master, V. A., Donskov, F., Suarez, C., Albiges, L., Rini, B., Tomita, Y., Kann, A. G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01658-0 · Cited by 253
Motzer, R. J., Ravaud, A., Patard, J.-J., Pandha, H. S., George, D. J., Patel, A., Chang, Y.-H., Escudier, B., Donskov, F., Magheli, A., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.09.008 · Cited by 218
Self-citationPowles, T., Albiges, L., Bex, A., Grünwald, V., Porta, C., Procopio, G., Schmidinger, M., Suárez, C., & de Velasco, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.014 · Cited by 193
Self-citationMotzer, R. J., Russo, P., Grünwald, V., Tomita, Y., Zurawski, B., Parikh, O., Buti, S., Barthélémy, P., Goh, J. C., Ye, D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02574-0 · Cited by 193
Haas, N. B., Manola, J., Dutcher, J. P., Flaherty, K. T., Uzzo, R. G., Atkins, M. B., DiPaola, R. S., & Choueiri, T. K. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0076 · Cited by 166
Self-citationEisen, T. G., Frangou, E., Oza, B., Ritchie, A. W. S., Smith, B., Kaplan, R. S., Davis, I. D., Stockler, M. R., Albiges, L. K., Escudier, B. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01800 · Cited by 135
Sun, M., Marconi, L. S., Eisen, T. G., Escudier, B. J., Giles, R. H., Haas, N. B., Harshman, L. C., Quinn, D. I., Larkin, J., Pal, S. K., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.05.002 · Cited by 90
Self-citationSpicer, J. D., Gao, S., Liberman, M., Kato, T., Tsuboi, M., Lee, S. H., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.052 · Cited by 86
Shah, N. J., Sura, S. D., Shinde, R., Shi, J., Singhal, P. K., Robert, N. J., Vogelzang, N. J., Perini, R. F., & Motzer, R. J. (2023) · European Urology Open Science · doi:10.1016/j.euros.2022.12.015 · Cited by 64
Self-citationMultiple and Repeated Testing of Primary, Coprimary, and Secondary Hypotheses
Maurer, W., Glimm, E., & Bretz, F. (2010) · Statistics in Biopharmaceutical Research · doi:10.1198/sbr.2010.10010 · Cited by 34
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Symeonides, S. N., Hajek, J., Ferguson, T., Chang, Y., Lee, J., Haas, N. B., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad231 · Cited by 27
Self-citationMori, K., Yanagisawa, T., Fukuokaya, W., Iwatani, K., Matsukawa, A., Katayama, S., Pradère, B., Laukhtina, E., Rajwa, P., Moschini, M., et al. (2023) · International Journal of Urology · doi:10.1111/iju.15319 · Cited by 15
Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers
Rofi, E., Re, M. D., Arrigoni, E., Rizzo, M., Fontanelli, L., Crucitta, S., Gianfilippo, G., Restante, G., Fogli, S., Porta, C., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102891 · Cited by 8
Cited by
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
Uppaluri, R., Haddad, R. I., Tao, Y., Le Tourneau, C., Lee, N. Y., Westra, W., Chernock, R., Tahara, M., Harrington, K. J., Klochikhin, A. L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415434 · Cited by 410
Renal Cell Carcinoma: A Review
Rose, T. L., & Kim, W. Y. (2024) · JAMA · doi:10.1001/jama.2024.12848 · Cited by 374
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V., Kanesvaran, R., Kitamura, H., McKay, R., Porta, C., Procopio, G., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.05.537 · Cited by 369
Self-citationEuropean Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
Bex, A., Ghanem, Y. A., Albiges, L., Bonn, S., Campi, R., Capitanio, U., Dabestani, S., Hora, M., Klatte, T., Kuusk, T., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.02.020 · Cited by 345
Self-citationAguiar-Ibáñez, R., Mbous, Y. P. V., Sharma, S., & Chawla, E. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1546447 · Cited by 17
Metadata
- Authors
- Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Chang, Y.-H., Lee, J.-L., Sarwar, N., Haas, N. B., Gurney, H., Sawrycki, P., Mahave, M., Gross-Goupil, M., Zhang, T., Burke, J. M., Doshi, G., Melichar, B., Kopyltsov, E., Alva, A., Oudard, S., Topart, D., Hammers, H., Kitamura, H., McDermott, D. F., Silva, A., Winquist, E., Cornell, J., Elfiky, A., Burgents, J. E., Perini, R. F., & Powles, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-18
- Volume
- 390
- Issue
- 15
- Pages
- 1359-1371
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4394892953
- Cited by
- 346
- References
- 29
- FWCI
- 88.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.